TY  - JOUR
A1  - Radermacher, Kim A.
A1  - Wingler, Kirstin
A1  - Kleikers, Pamela
A1  - Altenhöfer, Sebastian
A1  - Hermans, Johannes J. R.
A1  - Kleinschnitz, Christoph
A1  - Schmidt, Harald H. H. W.
T1  - The 1027th target candidate in stroke: Will NADPH oxidase hold up?
JF  - Experimental and Translational Stroke Medicine
N2  - As recently reviewed, 1026 neuroprotective drug candidates in stroke research have all failed on their road towards validation and clinical translation, reasons being quality issues in preclinical research and publication bias. Quality control guidelines for preclinical stroke studies have now been established. However, sufficient understanding of the underlying mechanisms of neuronal death after stroke that could be possibly translated into new therapies is lacking. One exception is the hypothesis that cellular death is mediated by oxidative stress. Oxidative stress is defined as an excess of reactive oxygen species (ROS) derived from different possible enzymatic sources. Among these, NADPH oxidases (NOX1-5) stand out as they represent the only known enzyme family that has no other function than to produce ROS. Based on data from different NOX knockout mouse models in ischemic stroke, the most relevant isoform appears to be NOX4. Here we discuss the state-of-the-art of this target with respect to stroke and open questions that need to be addressed on the path towards clinical translation.
KW  - NADPH oxidases (NOX)
KW  - stroke therapy
KW  - oxidative stress
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-124197
VL  - 4
IS  - 11
ER  - 
TY  - JOUR
A1  - Klotz, Barbara
A1  - Mentrup, Birgit
A1  - Regensburger, Martina
A1  - Zeck, Sabine
A1  - Schneidereit, Jutta
A1  - Schupp, Nicole
A1  - Linden, Christian
A1  - Merz, Cornelia
A1  - Ebert, Regina
A1  - Jakob, Franz
T1  - 1,25-Dihydroxyvitamin D3 Treatment Delays Cellular Aging in Human Mesenchymal Stem Cells while Maintaining Their Multipotent Capacity
JF  - PLoS ONE
N2  - 1,25-dihydroxyvitamin D3 (1,25D3) was reported to induce premature organismal aging in fibroblast growth factor-23 (Fgf23) and klotho deficient mice, which is of main interest as 1,25D3 supplementation of its precursor cholecalciferol is used in basic osteoporosis treatment. We wanted to know if 1,25D3 is able to modulate aging processes on a cellular level in human mesenchymal stem cells (hMSC). Effects of 100 nM 1,25D3 on hMSC were analyzed by cell proliferation and apoptosis assay, beta-galactosidase staining, VDR and surface marker immunocytochemistry, RT-PCR of 1,25D3-responsive, quiescence-and replicative senescence-associated genes. 1,25D3 treatment significantly inhibited hMSC proliferation and apoptosis after 72 h and delayed the development of replicative senescence in long-term cultures according to beta-galactosidase staining and P16 expression. Cell morphology changed from a fibroblast like appearance to broad and rounded shapes. Long term treatment did not induce lineage commitment in terms of osteogenic pathways but maintained their clonogenic capacity, their surface marker characteristics (expression of CD73, CD90, CD105) and their multipotency to develop towards the chondrogenic, adipogenic and osteogenic pathways. In conclusion, 1,25D3 delays replicative senescence in primary hMSC while the pro-aging effects seen in mouse models might mainly be due to elevated systemic phosphate levels, which propagate organismal aging.
KW  - perspectives
KW  - bone marrow
KW  - mutant mice
KW  - oxidative stress
KW  - transcription factors
KW  - vitamin-D-receptor
KW  - differentiation
KW  - tissue
KW  - 2',7'-dichlorofluorescin
KW  - homeostasis
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133392
VL  - 7
IS  - 1
ER  -